200
Participants
Start Date
July 31, 2025
Primary Completion Date
May 31, 2029
Study Completion Date
May 31, 2029
Psilocybin
One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally
Inactive Placebo
Two matching placebo capsules administered once orally
Supportive therapy sessions
Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
NYU Langone Health, New York
Silver Hill Hospital, New Canaan
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
NYU Langone Health
OTHER